Other languages Solasia Pharma K.K.

Equities

4597

JP3436500007

Market Closed - Japan Exchange Other stock markets 11:30:00 28/06/2024 am IST			5-day change	1st Jan Change
30 ^JPY	0.00%		+11.11%	-33.33%

15/05	Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024	CI
04/03	Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024	15/05
Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	28/12
Solasia Pharma Narrows Nine-Month Loss as Revenue Gains	14/11
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023	13/11
Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	10/23/10
Solasia Pharma K.K. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023	15/23/15
Solasia Partners with WEP Clinical to Supply Darvias [Darvias Injection 135Mg] Under a Named Patient Program	20/23/20
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2023	14/23/14
Solasia Pharma Flags Bigger FY22 Loss Following Unfavorable Results of Cancer Drug Study	28/22/28
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022	25/22/25
An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. from ITOCHU Corporation.	22/22/22
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022	14/22/14
Solasia Announces Summary of SP-04 PledOx Development Status	05/22/05
Solasia gibt Einführung von Darvias® in Japan bekannt	22/22/22
Solasia anuncia el lanzamiento de Darvias® en Japón	22/22/22
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022	15/22/15
Solasia Pharma K.K. Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin)	04/22/04
Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (OM : CAMX).	08/22/08
Solasia Pharma: DARVIAS® als Injektion mit 135 mg (generischer Name: DARINAPARSIN/Entwicklungscode: SP-02) in Japan zugelassen	20/22/20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Solasia Pharma K.K.

Equities

4597

JP3436500007

Other languages

Filters